KTTA Stock Overview A biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Pasithea Therapeutics Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for Pasithea Therapeutics Historical stock prices Current Share Price US$2.66 52 Week High US$9.40 52 Week Low US$2.37 Beta 0.73 1 Month Change -14.19% 3 Month Change -32.87% 1 Year Change -66.61% 3 Year Change -92.77% 5 Year Change n/a Change since IPO -96.26%
Recent News & Updates Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $2.076 million. Nov 27
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer Nov 20
New major risk - Financial position Nov 15 Pasithea Therapeutics Corp. announced that it has received $5.000003 million in funding Oct 01
Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding Sep 27
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board Sep 03 See more updates Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $2.076 million. Nov 27
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer Nov 20
New major risk - Financial position Nov 15 Pasithea Therapeutics Corp. announced that it has received $5.000003 million in funding Oct 01
Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding Sep 27
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board Sep 03
New minor risk - Share price stability Jul 30
Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial Jun 15
Pasithea Therapeutics Corp., Annual General Meeting, Jun 26, 2024 May 17
Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers Apr 25
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004 Feb 14
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position Jan 10
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients Jan 02
New major risk - Financial position Nov 20
Pasithea Therapeutics Corp. Selects PAS-003 Lead Development Candidate Nov 10
Pasithea Therapeutics Corp., Annual General Meeting, Nov 29, 2023 Oct 27
High number of new and inexperienced directors Oct 20
Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery Program Aug 02 Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.
New major risk - Share price stability Jul 21
Lucy Scientific Discovery Inc. (NasdaqCM:LSDI) made a proposal to acquire Pasithea Therapeutics Corp. (NasdaqCM:KTTA) for $22.2 million. Jun 07
Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement Jan 26
Concord IP2 Recommends Stockholders to Vote for Boardroom Change at Pasithea Therapeutics Dec 08
Price target decreased to US$2.30 Nov 16
Less than half of directors are independent Nov 16
Concord IP2 Ltd Files a Lawsuit Against the Directors of Pasithea Therapeutics Corp Nov 02
Camac Partners Comments on Pasithea Therapeutics’ Acquisition of AlloMek Therapeutics Oct 14 Pasithea Therapeutics Corp. (NasdaqCM:KTTA) acquired AlloMek Therapeutics, LLC from Integral Biosciences Private Limited, Innovation Pathways LLC, Shakti BioResearch LLC and others for $11.3 million.
Camac Partners LLC Sends a Letter to Pasithea Therapeutics Corp Sep 30
Less than half of directors are independent Sep 23
Pasithea Therapeutics Corp. Appoints Alfred J. Novak to Its Board of Directors Sep 21
Pasithea Therapeutics Corp. Appoints Dr. Merit Cudkowicz to its Scientific Advisory Board Sep 16 Camac Partners Provides Information to Shareholders of Pasithea Therapeutics
Camac Partners Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting Aug 26
Pasithea Therapeutics Corp. Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis Aug 12
Concord Investment Partners Ltd Urges Stockholders of Pasithea Therapeutics Corp to Call Special Meeting Aug 06
Concord IP2 Ltd Nominates Candidates to the Board of Pasithea Therapeutics Corp Jul 29
We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate Jul 21
Concord IP2 Ltd Files Solicitation Statement to Call a Special Meeting of Stockholders of Pasithea Therapeutics Corp Jul 02
Concord IP2 Ltd Provides Information to Shareholders of Pasithea Therapeutics Corp Jun 28
Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics Corp Jun 17
Stanley Gloss, the Chief Financial Officer of Pasithea Therapeutics Corp., Passes Away Jun 11
Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics Corp Jun 02
Pasithea Therapeutics Corp., Annual General Meeting, Jun 23, 2022 May 14
Less than half of directors are independent Apr 27
Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation Apr 06
Pasithea Therapeutics Appoints Daniel Weinberger to Its Scientific Advisory Board Feb 10
Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis Feb 04
Pasithea Therapeutics Corp. announced that it has received $30.38 million in funding Nov 30
Pasithea Therapeutics Corp. announced that it expects to receive $30.38 million in funding Nov 26
Pasithea Therapeutics Adds Esketamine Nasal Spray to Its Clinic Offerings in the U.K Nov 24 Shareholder Returns KTTA US Biotechs US Market 7D 2.3% -3.3% -2.2% 1Y -66.6% -1.9% 23.9%
See full shareholder returns
Return vs Industry: KTTA underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: KTTA underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is KTTA's price volatile compared to industry and market? KTTA volatility KTTA Average Weekly Movement 18.2% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: KTTA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KTTA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia.
Show more Pasithea Therapeutics Corp. Fundamentals Summary How do Pasithea Therapeutics's earnings and revenue compare to its market cap? KTTA fundamental statistics Market cap US$3.33m Earnings (TTM ) -US$15.76m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) KTTA income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$15.76m Earnings -US$15.76m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 08:54 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Pasithea Therapeutics Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research Constantine Davides D. Boral Capital LLC.
Show 0 more analysts 
